Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; phenol; sodium chloride - pneumovax 23 is indicated for immunisation of individuals in the following situations: all individuals over the age of 65 years; individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy; immunocompromised patients at increased risk of pneumococcal disease (eg patients with hiv infection before the development of aids, nephrotic syndrome, multiple myeloma, lymphoma, hodgkin's disease and organ transplantation); aboriginal and torres strait islander people over 50 years of age; immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg chronic cardiac, renal or pulmonary disease, diabetes mellitus, alcoholism and cirrhosis); patients with cerebrospinal fluid leaks. in australia, the national health and medical research council (nhmrc) currently recommends the vaccination of tobacco smokers with the 23-valent polysaccharide pneumococcal vaccine. pneumovax 23 is indicated for immunisation only against pneumococcal disease caused by those pneumococcal types included in the vaccine. effectiveness of the vaccine in the prevention of pneumococcal pneumonia and pneumococcal bacteremia has been demonstrated. in australia, the national health and medical research council (nhmrc) currently recommeds the vaccination of tabacco smokers with the 23-valent polysaccharide pneumococcal vaccine. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus othar those contained in the vaccine.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - pneumococcal vaccine polyvalent - solution for injection - pneumococcal vaccine polyvalent 25 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen - pneumococcus, purified polysaccharides antigen - for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; phenol; sodium chloride - pneumovax 23 is indicated for immunisation of individuals in the following situations: all individuals over the age of 65 years; individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy; immunocompromised patients at increased risk of pneumococcal disease (eg patients with hiv infection before the development of aids, nephrotic syndrome, multiple myeloma, lymphoma, hodgkin's disease and organ transplantation); aboriginal and torres strait islander people over 50 years of age; immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg chronic cardiac, renal or pulmonary disease, diabetes mellitus, alcoholism and cirrhosis); patients with cerebrospinal fluid leaks. in australia, the national health and medical research council (nhmrc) currently recommends the vaccination of tobacco smokers with the 23-valent

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection in pre-filled syringe - 25 mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection - 25mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen

Canada - English - Health Canada

merck canada inc - pneumococcal vaccine polyvalent - solution - 25mcg - pneumococcal vaccine polyvalent 25mcg - vaccines

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) - solution for injection - active: pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) excipient: phenol sodium chloride water for injection - pneumovax 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.

Malta - English - Medicines Authority

merck sharp & dohme b.v. waarderweg 39, haarlem noord-holland, 2031 bn, netherlands - pneumococcal polysaccharide, serotype, conjugated to, crm, b conjugated, to crm, f conjugated, n conjugated, v conjugated, a conjugated - solution for injection in a pre-filled syringe - pneumococcal polysaccharide serotype 3 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 5 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 6b conjugated to crm197 25 µg pneumococcal polysaccharide serotype 7f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 8 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 9n conjugated to crm197 25 µg pneumococcal polysaccharide serotype 9v conjugated to crm197 25 µg pneumococcal polysaccharide serotype 10a conjugated to crm197 25 µg pneumococcal polysaccharide serotype 11a conjugated to crm197 25 µg pneumococcal polysaccharide serotype 12f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 14 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 15b conjugated to crm197 25 µg pneumococcal polysaccharide serotype 17f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 17f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 19f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 19a conjugated to crm197 25 µg pneumococcal polysaccharide serotype 20 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 22f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 23f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 33f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 1 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 2 conjugated to crm197 25 µg - vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - pneumococcal vaccine - solution for injection - 25mcg/0.5m %v/v - pneumococcal vaccines

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

merck sharp and dohme llc, united states - pneumococcal (streptococcus pneumoniae) polysaccharide (serotype 1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19a, 19f, 20, 22f, 23f, 33f) - solution for injection - 50 µ/ml,